chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Precise stock market trend predictions with free real-time quotes for India, US, and European stocks. Whether you're looking for short-term gains or long-term growth, our expert advice ensures you make the best investment choices. chl limited (532992) expands into new market - Free Access to Investment Community ✌️【Market Analysis】✌️ Expert predictions and real-time data on global stock indices, metals, energy, and agricultural products to help you make more informed decisions and boost your investment returns. Benefit from cutting-edge market intelligence for steady growth.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Precise stock market trend predictions with free real-time quotes for India, US, and European stocks. Whether you're looking for short-term gains or long-term growth, our expert advice ensures you make the best investment choices. For 1.7 million children living with HIV, a new formulation of a drug for adults is now available – and it could make treatment easier and cheaper.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Free stock selection service with professional advisors offering the best investment portfolio for stable growth. The pediatric formulation of dolutegravir, a drug recommended as first-line HIV treatment by the World Health Organization, will come as a strawberry-flavored tablet that can be dissolved in water or juice, making it easier to give to children too young to swallow tablets.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Expert predictions with real-time stock trend analysis to help you quickly select high-potential stocks and grow capital. The pediatric formulation of dolutegravir was developed through a partnership between ViiV Healthcare (the company that first originated the drug), generic drug manufacturers, Unitaid (an international health-funding organization), and the Clinton Health Access Initiative.

On World AIDS Day Tuesday, Unitaid and Clinton Health Access Initiative released astatementabout the drug and announced a pricing agreement to make it available in low- and middle-income countries.

“The 10 mg scored dispersible tablet was developed by Viatris (Mylan) and Macleods based on the technical information provided by ViiV Healthcare,” Clinton Health Access Initiative spokeswoman Regan Lachapelle said in an email.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Free expert stock trend predictions to help you identify high-potential stocks and maximize returns. With real-time global market indices, futures, metals, energy, and agricultural product data, our platform enables you to make informed investment decisions. The drug can be taken by children above four weeks of age and weighing at least 6.6 pounds (3 kilograms), Lachapelle added.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Real-time stock market predictions and analysis, offering precise advice on top-performing stocks to help you seize the best opportunities for growth. Gain access to expert insights and global market data to make timely investment decisions. The flavoring will make the drug more palatable to children compared to current options that are bitter to the taste or otherwise hard for kids to consume, according to pediatric HIV experts.

In low- and middle-income countries, the pediatric formulation of dolutegravir will cost about $36 per child per year, based on the pricing agreement brokered by Unitaid and Clinton Health Access Initiative with generic manufacturers Viatris and Macleods.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Get accurate stock forecasts and market predictions from top financial advisors. With real-time updates on stock indices, exchange rates, and futures data, you'll be equipped to make profitable decisions and grow your capital steadily. Since dolutegravir is not a standalone treatment for HIV, and must be taken in conjunction with other drugs as part of a HIV therapy regimen, the overall cost of treatment under the new pricing agreement will go from over $480 to under $120 per child per year, according to Unitaid and Clinton Access Health Initiative.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Take advantage of our free stock market analysis and real-time data to help you choose the best investment options. Our expert predictions and tailored strategies ensure you can achieve stable returns and mitigate risks effectively. The drug will become available in Benin, Kenya, Malawi, Nigeria, Uganda and Zimbabwe in the first half of 2021, and in more countries later on, Unitaid and Clinton Health Initiative wrote.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Expert predictions with real-time stock trends, futures prices, and exchange rate fluctuations to help you select the right stocks and achieve your financial goals. Stay ahead of the curve with accurate, real-time investment insights. An estimated 100,000 children died of AIDS-related illnesses in 2018,accordingto the World Health Organization. Without access to testing and treatment, the WHO says that 50% of children affected by HIV will die by the age of 2, and 80% will die before turning 5.

“If infants get treated and their virus stays suppressed or controlled, they can live into their 3rd, 4th or perhaps even 5th decade of life—or longer,” Dr. Deborah Persaud, a professor of pediatrics at Johns Hopkins University and an expert in HIV/AIDS in children, told 【 - Free Access to Investment Community 】.

“Even if they are on treatment, for many years they have been on suboptimal drugs, because it always takes longer to develop and approve medications for children compared to adults,” Dr. Martina Penazzato, the HIV lead at the World Health Organization, told 【 - Free Access to Investment Community 】.

Penazzato said the formulation of pediatric dolutegravir could be “quite transformative” in the fight against pediatric HIV.

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Free access to real-time stock market data analysis, global market trends, and expert predictions. Capture emerging opportunities and grow your portfolio steadily, with insights into metals, energy, and agricultural products. The drug was “a missing formulation to allow the provision of the preferred regimen by WHO for children living with HIV,” Penazzato said.

ViiV Healthcare’s pediatric dolutegravir received US Food and Drug Administration approval in June, and the generic product received tentative approval on November 19 under the US President’s Emergency Plan for AIDS Relief (PEPFAR).

“This is the first time a generic product has been positively reviewed within several months of the originator product receiving FDA approval, reducing the gap from three years for the adult version of the same medicine to just five months,” Unitaid and Clinton Health Access Initiative wrote.

“FDA tentative approval via the President’s Emergency Plan for AIDS Relief (PEPFAR) program allows procurement of the product by US agencies such as PEPFAR, USAID,” Lachapelle said in an email.

“Each generic company is also in the process of registering the products within the countries where it will be used.”

chl limited (532992) expands into new market ✌️【Market Analysis】✌️ Professional investment advisors provide up-to-the-minute market data, helping you analyze stock trends and select high-potential stocks. Achieve capital growth with well-researched strategies based on expert insights.